Pfizer Inc. (NYSE:PFE) EVP Rady A. Johnson sold 27,323 shares of the company’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total transaction of $998,655.65. Following the sale, the executive vice president now directly owns 70,332 shares of the company’s stock, valued at approximately $2,570,634.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Pfizer Inc. (NYSE:PFE) traded down $0.40 during mid-day trading on Wednesday, reaching $36.35. 22,180,651 shares of the company were exchanged, compared to its average volume of 28,010,000. The firm has a market cap of $216,390.00, a PE ratio of 20.77, a price-to-earnings-growth ratio of 2.06 and a beta of 0.91. Pfizer Inc. has a twelve month low of $31.67 and a twelve month high of $39.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.47 EPS. analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date was Thursday, February 1st. Pfizer’s dividend payout ratio is currently 77.71%.
A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Earnest Partners LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $105,000. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter valued at $103,000. First Dallas Securities Inc. bought a new stake in shares of Pfizer in the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in shares of Pfizer in the 4th quarter valued at $118,000. Finally, Delpha Capital Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $126,000. Hedge funds and other institutional investors own 71.41% of the company’s stock.
A number of brokerages have recently weighed in on PFE. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, January 30th. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 price target (up previously from $33.00) on shares of Pfizer in a report on Monday, January 29th. Morgan Stanley upped their price target on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. UBS Group set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $39.40.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/pfizer-inc-pfe-evp-sells-998655-65-in-stock.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.